Tuesday, October 6, 2026

Gilead and Calm address emotional burden in serious illness

Gilead is placing greater emphasis on the mental and emotional impact of serious disease. On October 5, 2026, the company described a collaboration with Calm that gives people living with cancer, HIV and primary biliary cholangitis, as well as caregivers, free access to selected mindfulness resources.

The program is positioned as part of Gilead’s broader view of health support. Beyond medical treatment, the company is highlighting the strain that can accompany diagnosis, treatment, recurrence and chronic symptoms.

Patient experiences shape the initiative

Gilead points to the experience of Kayla, a young Black woman living with stage 4 metastatic breast cancer. She was first diagnosed with stage 2 breast cancer in 2022. After the disease returned as advanced cancer, she found that many available support options did not fully reflect her life stage or background.

Her experience included questions around fertility and future planning. Gilead’s account underlines how age, identity and underrepresentation can influence whether patients find emotional support that feels relevant to them.

The company also describes the experience of Juliska, who is living with stage 4 triple-negative breast cancer. Traditional support groups were not always helpful for her, while social work support, therapy and time outdoors became important parts of managing anxiety and emotional strain.

Emotional needs across cancer, HIV and PBC

Gilead frames the initiative against a wider burden of distress. Citing the National Cancer Institute, the company says about half of people with cancer report distress and around two in ten report symptoms of depression. For people living with HIV in the United States, Gilead cites information from the National Institutes of Health and the Centers for Disease Control and Prevention indicating that more than one-third experience depression and around 28 percent have an anxiety disorder.

For people with primary biliary cholangitis, symptoms such as fatigue, chronic itching, brain fog and sleep disruption can affect work, relationships and overall wellbeing. The Calm resources are intended to be curated for the needs of each patient community and for caregivers.

Relevance for pharma communications

The collaboration illustrates how pharmaceutical companies are broadening patient support beyond medicine alone. For Gilead, the emphasis is on reaching people during emotionally difficult phases of illness. From a B2B perspective, the program sits at the intersection of patient engagement, digital content and condition-specific communication.

Access is central: the resources are offered free of charge and are designed to meet patients and caregivers at different stages of their health journey. Gilead presents the initiative as complementary support for emotional wellbeing, not as a substitute for medical or mental health care.